Healthcare of Ontario Pension Plan Trust Fund raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 37.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 133,891 shares of the company’s stock after purchasing an additional 36,281 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund owned 0.17% of IDEXX Laboratories worth $75,232,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently made changes to their positions in the business. SHP Wealth Management purchased a new stake in IDEXX Laboratories during the fourth quarter valued at approximately $26,000. Virtus Advisers LLC bought a new position in IDEXX Laboratories during the third quarter valued at $26,000. Mowery & Schoenfeld Wealth Management LLC raised its stake in shares of IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 20 shares during the period. Wormser Freres Gestion raised its stake in shares of IDEXX Laboratories by 671.4% in the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 47 shares during the period. Finally, WealthCollab LLC bought a new stake in shares of IDEXX Laboratories in the 2nd quarter worth about $30,000. 87.84% of the stock is currently owned by institutional investors.
IDEXX Laboratories Trading Up 0.9%
NASDAQ:IDXX opened at $544.32 on Friday. The stock has a market capitalization of $42.94 billion, a price-to-earnings ratio of 40.08, a PEG ratio of 2.98 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52 week low of $518.55 and a 52 week high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The firm has a 50 day moving average of $556.27 and a 200 day moving average of $595.41.
Analyst Ratings Changes
IDXX has been the topic of several analyst reports. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. UBS Group dropped their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Finally, Citigroup began coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.
View Our Latest Research Report on IDEXX Laboratories
About IDEXX Laboratories
IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Further Reading
- Five stocks we like better than IDEXX Laboratories
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
